AP382A - A pharmaceutical composition comprising a benzopyran-3-OL. - Google Patents

A pharmaceutical composition comprising a benzopyran-3-OL. Download PDF

Info

Publication number: AP382A
Authority: AP; ARIPO
Prior art keywords: pharmaceutically acceptable; compound; pharmaceutical composition; acceptable salt; administration
Prior art date: 1991-12-05

Application number

APAP/P/1992/000454A

Other languages

English (en)

Other versions

AP9200454A0 (en

Inventor

Jonathan Robert Sanders Arch

Nicholas Edward Bowring

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-05

Filing date

1992-12-04

Publication date

1995-05-03

1991-12-05 Priority claimed from GB919125862A external-priority patent/GB9125862D0/en

1992-06-19 Priority claimed from GB929213042A external-priority patent/GB9213042D0/en

1992-12-04 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

1993-01-31 Publication of AP9200454A0 publication Critical patent/AP9200454A0/xx

1995-05-03 Application granted granted Critical

1995-05-03 Publication of AP382A publication Critical patent/AP382A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
LKXADRQJLNYNQL-UHFFFAOYSA-N 2h-chromen-3-ol Chemical compound C1=CC=C2OCC(O)=CC2=C1 LKXADRQJLNYNQL-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 36
239000000203 mixture Substances 0.000 claims description 26
150000003839 salts Chemical class 0.000 claims description 17
239000012453 solvate Substances 0.000 claims description 17
239000003937 drug carrier Substances 0.000 claims description 11
238000000034 method Methods 0.000 claims description 9
239000000843 powder Substances 0.000 claims description 7
ZSUFQZNGDIXQAD-CABCVRRESA-N 1-[(3s,4r)-3-hydroxy-2,2-dimethyl-6-(1,1,2,2,2-pentafluoroethyl)-3,4-dihydrochromen-4-yl]piperidin-2-one Chemical compound N1([C@@H]2C3=CC(=CC=C3OC([C@H]2O)(C)C)C(F)(F)C(F)(F)F)CCCCC1=O ZSUFQZNGDIXQAD-CABCVRRESA-N 0.000 claims description 5
208000018569 Respiratory Tract disease Diseases 0.000 claims description 5
239000000443 aerosol Substances 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
210000002345 respiratory system Anatomy 0.000 claims description 4
239000006199 nebulizer Substances 0.000 claims description 3
238000007911 parenteral administration Methods 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims description 2
239000003981 vehicle Substances 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
206010062109 Reversible airways obstruction Diseases 0.000 description 4
208000006673 asthma Diseases 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 4
229960002329 methacholine Drugs 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000011049 filling Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000003826 tablet Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
241000220479 Acacia Species 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229940124630 bronchodilator Drugs 0.000 description 2
239000000168 bronchodilator agent Substances 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229940055577 oleyl alcohol Drugs 0.000 description 2
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
241000700159 Rattus Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
229960003556 aminophylline Drugs 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
150000001562 benzopyrans Chemical class 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001175 calcium sulphate Substances 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
229960002179 ephedrine Drugs 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229960001268 isoetarine Drugs 0.000 description 1
229960001317 isoprenaline Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000003607 modifier Substances 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229960001802 phenylephrine Drugs 0.000 description 1
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
238000007789 sealing Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000002278 tabletting lubricant Substances 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

APAP/P/1992/000454A 1991-12-05 1992-12-04 A pharmaceutical composition comprising a benzopyran-3-OL. AP382A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB919125862A GB9125862D0 (en)	1991-12-05	1991-12-05	Pharmaceutical composition
GB929213042A GB9213042D0 (en)	1992-06-19	1992-06-19	Pharmaceutical composition

Publications (2)

Publication Number	Publication Date
AP9200454A0 AP9200454A0 (en)	1993-01-31
AP382A true AP382A (en)	1995-05-03

Family

ID=26299960

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1992/000454A AP382A (en)	1991-12-05	1992-12-04	A pharmaceutical composition comprising a benzopyran-3-OL.

Country Status (15)

Country	Link
EP (1)	EP0615437A1 (fr)
JP (1)	JPH07501538A (fr)
AP (1)	AP382A (fr)
AU (1)	AU2954292A (fr)
BR (1)	BR9206845A (fr)
CA (1)	CA2125156A1 (fr)
CZ (1)	CZ136394A3 (fr)
HU (1)	HUT70745A (fr)
IL (1)	IL103952A0 (fr)
MA (1)	MA22731A1 (fr)
MX (1)	MX9206975A (fr)
RU (1)	RU94030464A (fr)
SI (1)	SI9200365A (fr)
SK (1)	SK65794A3 (fr)
WO (1)	WO1993010757A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0076075A1 (fr) *	1981-09-25	1983-04-06	Beecham Group Plc	Dérivés de benzopyranes pharmacologiquement actifs
EP0093535A1 (fr) *	1982-04-28	1983-11-09	Beecham Group Plc	Chromènes et chromanes
EP0296975A1 (fr) *	1987-06-23	1988-12-28	MERCK PATENT GmbH	Dérivés du diméthyl-2,2 chromannol-3, procédé d'obtention et compositions pharmaceutiques les contenant
EP0376524A1 (fr) *	1988-12-13	1990-07-04	Beecham Group Plc	Benzopyrane et composés apparentés

1992
- 1992-12-01 CZ CZ941363A patent/CZ136394A3/cs unknown
- 1992-12-01 RU RU94030464/14A patent/RU94030464A/ru unknown
- 1992-12-01 WO PCT/GB1992/002234 patent/WO1993010757A1/fr not_active Ceased
- 1992-12-01 JP JP5509963A patent/JPH07501538A/ja active Pending
- 1992-12-01 EP EP92923956A patent/EP0615437A1/fr not_active Withdrawn
- 1992-12-01 CA CA002125156A patent/CA2125156A1/fr not_active Abandoned
- 1992-12-01 AU AU29542/92A patent/AU2954292A/en not_active Abandoned
- 1992-12-01 HU HU9401681A patent/HUT70745A/hu unknown
- 1992-12-01 SK SK657-94A patent/SK65794A3/sk unknown
- 1992-12-01 BR BR9206845A patent/BR9206845A/pt not_active Application Discontinuation
- 1992-12-03 IL IL103952A patent/IL103952A0/xx unknown
- 1992-12-03 MA MA23021A patent/MA22731A1/fr unknown
- 1992-12-03 MX MX9206975A patent/MX9206975A/es unknown
- 1992-12-04 AP APAP/P/1992/000454A patent/AP382A/en active
- 1992-12-04 SI SI19929200365A patent/SI9200365A/sl unknown

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0076075A1 (fr) *	1981-09-25	1983-04-06	Beecham Group Plc	Dérivés de benzopyranes pharmacologiquement actifs
EP0093535A1 (fr) *	1982-04-28	1983-11-09	Beecham Group Plc	Chromènes et chromanes
EP0296975A1 (fr) *	1987-06-23	1988-12-28	MERCK PATENT GmbH	Dérivés du diméthyl-2,2 chromannol-3, procédé d'obtention et compositions pharmaceutiques les contenant
EP0376524A1 (fr) *	1988-12-13	1990-07-04	Beecham Group Plc	Benzopyrane et composés apparentés

Also Published As

Publication number	Publication date
SK65794A3 (en)	1995-02-08
IL103952A0 (en)	1993-05-13
MX9206975A (es)	1993-06-01
HU9401681D0 (en)	1994-09-28
SI9200365A (en)	1993-06-30
CA2125156A1 (fr)	1993-06-10
AU2954292A (en)	1993-06-28
BR9206845A (pt)	1996-01-02
JPH07501538A (ja)	1995-02-16
CZ136394A3 (en)	1995-02-15
AP9200454A0 (en)	1993-01-31
RU94030464A (ru)	1996-04-27
WO1993010757A1 (fr)	1993-06-10
HUT70745A (en)	1995-10-30
EP0615437A1 (fr)	1994-09-21
MA22731A1 (fr)	1993-07-01

Publication	Publication Date	Title
JP4445590B2 (ja)	2010-04-07	パロキセチン−レジン含有の経口液体組成物
US4891380A (en)	1990-01-02	Novel treatment
EP0277352A1 (fr)	1988-08-10	Association synergétique d'azélastine et de théophylline ou d'azélastine et de bêta-mimétiques
JP2008512429A (ja)	2008-04-24	ロフルミラストとｓｙｋインヒビターとの組合せ物並びにその使用方法
AP382A (en)	1995-05-03	A pharmaceutical composition comprising a benzopyran-3-OL.
EP1720543A1 (fr)	2006-11-15	Melange de roflumilast et de glycopryrronium
EP0222575A1 (fr)	1987-05-20	Mélange prazosine-pirbutérol pour la bronchodilatation
WO2009112436A1 (fr)	2009-09-17	Composition à libération modifiée comprenant de la doxofylline
US7932276B2 (en)	2011-04-26	Agent for curing chronic obstructive pulmonary disease
JPH07505381A (ja)	1995-06-15	気道炎症および気道過応答性の治療薬
JPH07138157A (ja)	1995-05-30	抗潰瘍剤
CN113577059B (zh)	2022-05-20	一种用于小儿哮喘的活性药物
US6297268B1 (en)	2001-10-02	Imidazoles as cholesterol lowering agents
JPH085784B2 (ja)	1996-01-24	シロツプ剤
ZA200100360B (en)	2002-03-12	Method of treatment.
AU2002317509B2 (en)	2007-03-08	Use of thiazole deirvatives for the manufacture of a medicament for the treatment of chronic obstructure pulmonary disease
JP2001089375A (ja)	2001-04-03	感冒用組成物
JP2003095946A (ja)	2003-04-03	ファモチジン錠剤
JPH0776584A (ja)	1995-03-20	内皮細胞障害抑制剤
WO2002019995A2 (fr)	2002-03-14	Utilisation d'une combinaison pharmaceutique
CN1080171A (zh)	1994-01-05	药用组合物
JPH07179346A (ja)	1995-07-18	胃腸治療剤
US20080269179A1 (en)	2008-10-30	Use of Megestrol Acetate for the Treatment of Obstructive Pulmonary Diseases
WO1993000091A1 (fr)	1993-01-07	Procedes et compositions pour le traitement de troubles pulmonaires et cardiaques utlisant un (-)pirbuterol optiquement pur
WO1993000090A1 (fr)	1993-01-07	Methodes et compositions pour le traitement des troubles pulmonaires et cardiaques avec du pirbuterol optiquement pur (+)